Pacira BioSciences (PCRX) Short Interest Ratio & Short Volume $25.30 +0.88 (+3.60%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$24.66 -0.65 (-2.55%) As of 03/27/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Pacira BioSciences Short Interest DataPacira BioSciences (PCRX) has a short interest of 5.93 million shares, representing 13.72% of the float (the number of shares available for trading by the public). This marks a 1.19% increase in short interest from the previous month. The short interest ratio (days to cover) is 6.9, indicating that it would take 6.9 days of the average trading volume of 913,270 shares to cover all short positions.Current Short Interest5,930,000 sharesPrevious Short Interest5,860,000 sharesChange Vs. Previous Month+1.19%Dollar Volume Sold Short$135.62 millionShort Interest Ratio6.9 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares46,276,000 sharesShort Percent of Float13.72%Today's Trading Volume803,782 sharesAverage Trading Volume913,270 sharesToday's Volume Vs. Average88% Short Selling Pacira BioSciences? Sign up to receive the latest short interest report for Pacira BioSciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPCRX Short Interest Over TimePCRX Days to Cover Over TimePCRX Percentage of Float Shorted Over Time Remove Ads Pacira BioSciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/20255,930,000 shares $135.62 million +1.2%13.7%6.9 $22.87 2/28/20255,860,000 shares $140.93 million +10.6%13.6%6.8 $24.05 2/15/20255,300,000 shares $134.83 million +3.1%12.3%6.5 $25.44 1/31/20255,140,000 shares $135.34 million -5.5%N/A6.4 $26.33 1/15/20255,440,000 shares $119.03 million +24.8%N/A7.4 $21.88 12/31/20244,360,000 shares $82.14 million -8.2%N/A6.4 $18.84 12/15/20244,750,000 shares $94.34 million -1.0%N/A6.6 $19.86 11/30/20244,800,000 shares $81.17 million -0.4%N/A6 $16.91 11/15/20244,820,000 shares $80.01 million -11.7%N/A6.2 $16.60 10/31/20245,460,000 shares $90.64 million -11.1%N/A5.3 $16.60 Get the Latest News and Ratings for PCRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. 10/15/20246,140,000 shares $102.48 million -2.7%N/A5.3 $16.69 9/30/20246,310,000 shares $94.97 million +9.7%N/A5 $15.05 9/15/20245,750,000 shares $75.38 million -5.0%N/A4 $13.11 8/31/20246,050,000 shares $94.14 million +17.5%N/A4.5 $15.56 8/15/20245,150,000 shares $68.75 million -18.4%N/A4 $13.35 7/31/20246,310,000 shares $130.30 million -2.9%N/A5.3 $20.65 7/15/20246,500,000 shares $138.45 million -3.4%N/A6.2 $21.30 6/30/20246,730,000 shares $192.55 million +5.8%N/A7.2 $28.61 6/15/20246,360,000 shares $178.91 million -1.1%N/A8.8 $28.13 5/31/20246,430,000 shares $195.02 million +6.5%N/A9.9 $30.33 5/15/20246,040,000 shares $181.68 million +67.8%N/A9.4 $30.08 4/30/20243,600,000 shares $94.50 million +4.4%N/A6.7 $26.25 4/15/20243,450,000 shares $91.53 million -7.8%N/A7 $26.53 3/31/20243,740,000 shares $109.28 million -8.1%N/A7.5 $29.22 3/15/20244,070,000 shares $119.70 million -2.4%N/A8.1 $29.41 2/29/20244,170,000 shares $123.93 million +5.8%N/A7.4 $29.72 2/15/20243,940,000 shares $116.86 million +1.0%N/A7.4 $29.66 1/31/20243,900,000 shares $127.10 million +4.6%N/A6.9 $32.59 1/15/20243,730,000 shares $120.18 million +6.9%N/A7 $32.22 12/31/20233,490,000 shares $117.75 million +7.4%N/A6.5 $33.74 12/15/20233,250,000 shares $101.69 million -0.9%N/A5.8 $31.29 11/30/20233,280,000 shares $89.48 million +2.8%N/A6.7 $27.28 11/15/20233,190,000 shares $91.11 million -11.1%N/A6.4 $28.56 10/31/20233,590,000 shares $101.45 million -8.7%N/A7.5 $28.26 10/15/20233,930,000 shares $114.52 million +12.0%N/A7.7 $29.14 9/30/20233,510,000 shares $107.69 million -0.3%N/A6.5 $30.68 9/15/20233,520,000 shares $118.41 million -1.4%N/A6.8 $33.64 8/31/20233,570,000 shares $126.02 million -4.8%N/A6.3 $35.30 8/15/20233,750,000 shares $139.91 million +9.7%N/A6.6 $37.31 7/31/20233,420,000 shares $124.32 million -3.4%N/A5.9 $36.35Elon Warns: Exec Order 14024 Targets Dollar (Ad)Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.Go Here to Learn What's Happening and How to Prepare >> 7/15/20233,540,000 shares $132.01 million -2.5%N/A6 $37.29 6/30/20233,630,000 shares $145.45 million -0.6%N/A6.3 $40.07 6/15/20233,650,000 shares $147.17 million +3.7%N/A6.6 $40.32 5/31/20233,520,000 shares $133.87 million +4.5%N/A6.6 $38.03 5/15/20233,370,000 shares $143.12 million +7.7%N/A5.9 $42.47 4/30/20233,130,000 shares $141.82 million +4.0%N/A5.4 $45.31 4/15/20233,010,000 shares $127.77 million No ChangeN/A5.5 $42.45 3/31/20233,010,000 shares $122.84 million -10.4%N/A5.6 $40.81 3/15/20233,360,000 shares $132.25 million -5.9%N/A6.1 $39.36 2/28/20233,570,000 shares $151.97 million No ChangeN/A6.1 $42.57 2/15/20233,570,000 shares $144.91 million -20.7%N/A6.6 $40.59 1/31/20234,500,000 shares $176.72 million -12.8%N/A8.6 $39.27 1/15/20235,160,000 shares $193.09 million +4.2%N/A9.9 $37.42 12/30/20224,950,000 shares $191.12 million +7.1%N/A9.9 $38.61 12/15/20224,620,000 shares $184.38 million -6.3%N/A10.1 $39.91 11/30/20224,930,000 shares $237.87 million -10.5%N/A12.6 $48.25 11/15/20225,510,000 shares $275.50 million +0.7%N/A14.4 $50.00 10/31/20225,470,000 shares $283.13 million +1.7%N/A15.3 $51.76 10/15/20225,380,000 shares $277.61 million +4.3%N/A15.3 $51.60 9/30/20225,160,000 shares $274.46 million +2.2%N/A13.9 $53.19 9/15/20225,050,000 shares $274.06 million +4.3%N/A12.7 $54.27 8/31/20224,840,000 shares $254.00 million +3.9%N/A11.3 $52.48 8/15/20224,660,000 shares $269.02 million +1.8%N/A10.7 $57.73 7/31/20224,580,000 shares $259.04 million -0.2%N/A9.7 $56.56 7/15/20224,590,000 shares $252.45 million +5.8%N/A9.2 $55.00 6/30/20224,340,000 shares $253.02 million -12.9%N/A8.3 $58.30 6/15/20224,980,000 shares $271.66 million -3.1%12.5%9.4 $54.55 5/31/20225,140,000 shares $325.11 million +0.2%N/A9.9 $63.25 5/15/20225,130,000 shares $315.75 million -3.9%N/A9.2 $61.55 4/30/20225,340,000 shares $398.20 million +3.5%N/A9.5 $74.57 4/15/20225,160,000 shares $385.35 million -8.0%11.8%9.3 $74.68 3/31/20225,610,000 shares $428.16 million -3.3%12.9%10.3 $76.32 3/15/20225,800,000 shares $409.42 million -7.9%13.3%11.6 $70.59 2/28/20226,300,000 shares $420.15 million -4.8%14.4%12 $66.69 2/15/20226,620,000 shares $428.58 million -1.1%15.3%13.3 $64.74 1/31/20226,690,000 shares $419.93 million +5.2%15.4%13.5 $62.77 1/15/20226,360,000 shares $407.55 million -6.5%14.7%13.2 $64.08 12/31/20216,800,000 shares $409.16 million -0.2%15.7%14.5 $60.17 12/15/20216,810,000 shares $392.05 million -0.7%15.7%13.1 $57.57 11/30/20216,860,000 shares $360.97 million +4.9%15.8%13.8 $52.62 11/15/20216,540,000 shares $366.17 million -3.8%15.1%14.3 $55.99 10/29/20216,800,000 shares $355.50 million +3.8%15.7%15 $52.28 10/15/20216,550,000 shares $348.46 million -5.4%15.1%14.8 $53.20 9/30/20216,920,000 shares $387.52 million -3.4%16.0%16.4 $56.00 9/15/20217,160,000 shares $395.09 million +5.6%16.5%20.6 $55.18 8/31/20216,780,000 shares $401.99 million +1.8%15.6%17.6 $59.29 8/13/20216,660,000 shares $388.41 million -1.3%15.4%17 $58.32 7/30/20216,750,000 shares $397.91 million -2.7%15.6%16.1 $58.95 7/15/20216,940,000 shares $389.13 million +3.1%16.2%16.4 $56.07 6/30/20216,730,000 shares $408.38 million -4.3%15.7%14.9 $60.68Elon Warns: Exec Order 14024 Targets Dollar (Ad)Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.Go Here to Learn What's Happening and How to Prepare >> 6/15/20217,030,000 shares $419.55 million -0.9%16.4%15.3 $59.68 5/28/20217,090,000 shares $430.15 million +1.9%16.5%16.2 $60.67 5/14/20216,960,000 shares $427.76 million -2.8%N/A16.3 $61.46 4/30/20217,160,000 shares $459.67 million -0.3%N/A16.6 $64.20 4/15/20217,180,000 shares $498.51 million -3.5%N/A15.9 $69.43 3/31/20217,440,000 shares $526.90 million +5.5%N/A15.4 $70.82 3/15/20217,050,000 shares $517.96 million +4.4%N/A14.6 $73.47 2/26/20216,750,000 shares $502.54 million +13.8%N/A13.8 $74.45 2/12/20215,930,000 shares $466.69 million -4.8%N/A12 $78.70 1/29/20216,230,000 shares $416.97 million -5.2%N/A12.5 $66.93 1/15/20216,570,000 shares $506.94 million -6.8%N/A13.5 $77.16 12/31/20207,050,000 shares $413.91 million +13.5%N/A15.4 $58.71 12/15/20206,210,000 shares $365.77 million +8.8%N/A14.5 $58.90 11/30/20205,710,000 shares $364.30 million -3.9%N/A12.9 $63.80 11/15/20205,940,000 shares $378.02 million -2.6%N/A13.5 $63.64 10/30/20206,100,000 shares $324.03 million +5.5%N/A13.6 $53.12 10/15/20205,780,000 shares $335.47 million +1.9%N/A11.2 $58.04 9/30/20205,670,000 shares $340.88 million -8.7%N/A10.4 $60.12 9/15/20206,210,000 shares $367.69 million -3.0%N/A8.6 $59.21 8/31/20206,400,000 shares $400.13 million -11.4%N/A8.9 $62.52 8/14/20207,220,000 shares $442.08 million -11.2%N/A9.6 $61.23 7/31/20208,130,000 shares $427.72 million +1.0%N/A10.7 $52.61 7/15/20208,050,000 shares $445.41 million +23.9%N/A11.3 $55.33 6/30/20206,500,000 shares $341.06 million +18.2%N/A9 $52.47 6/15/20205,500,000 shares $238.76 million +3.2%N/A9 $43.41 5/29/20205,330,000 shares $234.25 million +1.1%N/A7.3 $43.95 5/15/20205,270,000 shares $212.28 million +1.9%N/A7.1 $40.28 4/30/20205,170,000 shares $213.47 million +11.9%N/A7 $41.29 4/15/20204,620,000 shares $164.01 million +16.7%N/A6.6 $35.50 3/31/20203,960,000 shares $157.57 million -8.6%N/A5.7 $39.79 PCRX Short Interest - Frequently Asked Questions What is Pacira BioSciences' current short interest? Short interest is the volume of Pacira BioSciences shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 5,930,000 shares of PCRX short. 13.72% of Pacira BioSciences' shares are currently sold short. Learn More on Pacira BioSciences' current short interest. What is a good short interest ratio for Pacira BioSciences? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PCRX shares currently have a short interest ratio of 7.0. Learn More on Pacira BioSciences's short interest ratio. Which institutional investors are shorting Pacira BioSciences? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Pacira BioSciences: Nomura Holdings Inc., Group One Trading LLC, Citadel Advisors LLC, Parallax Volatility Advisers L.P., Two Seas Capital LP, Susquehanna International Group LLP, HAP Trading LLC, Concourse Financial Group Securities Inc., and Wolverine Asset Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Pacira BioSciences? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 13.72% of Pacira BioSciences' floating shares are currently sold short. Is Pacira BioSciences' short interest increasing or decreasing? Pacira BioSciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 5,930,000 shares, an increase of 1.2% from the previous total of 5,860,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Pacira BioSciences' short interest compare to its competitors? 13.72% of Pacira BioSciences' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Pacira BioSciences: Perrigo Company plc (2.80%), Supernus Pharmaceuticals, Inc. (10.04%), Omeros Co. (17.16%), Nektar Therapeutics (3.87%), Cumberland Pharmaceuticals Inc. (3.76%), Assembly Biosciences, Inc. (0.52%), Eli Lilly and Company (0.75%), Johnson & Johnson (1.03%), AbbVie Inc. (1.12%), Merck & Co., Inc. (1.47%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short Pacira BioSciences stock? Short selling PCRX is an investing strategy that aims to generate trading profit from Pacira BioSciences as its price is falling. PCRX shares are trading up $0.88 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Pacira BioSciences? A short squeeze for Pacira BioSciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PCRX, which in turn drives the price of the stock up even further. How often is Pacira BioSciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PCRX, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies Perrigo Short Interest Data Supernus Pharmaceuticals Short Interest Data Omeros Short Interest Data Nektar Therapeutics Short Interest Data Cumberland Pharmaceuticals Short Interest Data Assembly Biosciences Short Interest Data Eli Lilly and Company Short Interest Data Johnson & Johnson Short Interest Data AbbVie Short Interest Data Merck & Co., Inc. Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PCRX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
